Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NSCLC, metastatic

2041 - LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC)


09 Oct 2016


NSCLC, metastatic


Atsushi Horiike


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


A. Horiike1, K. Yoh2, T. Seto3, M. Satouchi4, M. Nishio1, N. Yamamoto5, H. Murakami6, N. Nogami7, S. Nomura8, A. Sato9, A. Ohtsu10, K. Goto2

Author affiliations

  • 1 Department Of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 - Tokyo/JP
  • 2 Department Of Thoracic Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 3 Department Of Thoracic Oncology, National Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 4 Thoracic Oncology, Hyogo Cancer Center, 673-8558 - Akashi/JP
  • 5 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 6 Division Of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka/JP
  • 7 Respiratory Medicine, Shikoku Cancer Center, Matsuyama/JP
  • 8 Biostatistics Division, Center For Research Administration And Support, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 9 Office Of Clinical Research Support, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 10 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP


Abstract 2041


RET rearrangements were identified as a new rare oncogenic alteration in NSCLC. Vandetanib is a multi-targeted tyrosine kinase inhibitor having RET kinase inhibitory activity.


This was a multicenter, single-arm phase 2 study to evaluate the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC who failed at least one prior chemotherapy. Vandetanib was administered orally at 300 mg once daily in 28-day cycles. RET positive-patients were screened by a nationwide genomic screening project with approximately 200 institutions in Japan participating (LC-SCRUM-Japan). The primary endpoint was the independently assessed objective response rate (ORR). Exploratory subgroup analyses for ORR and progression-free survival (PFS) were performed with the factors including sex, smoking status, and type of RET fusions.


With screening of 1536 advanced NSCLC patients in the LC-SCRUM-Japan, 34 RET positive-patients (2%) were identified. A total of 19 patients (10 KIF5B-RET, 6 CCDC6-RET, and 3 unknown) were enrolled in this study and 17 patients were eligible for primary efficacy analysis. Half of the patients had been heavily treated with 3 or more prior chemotherapy (range, 1 to 12). Among 17 eligible patients, ORR was 53% (90% CI, 31 to 74) of which 9 partial responses and no complete response met the primary endpoint. Of 19 patients in ITT population, disease control rate was 90% and median PFS was 4.7 months (95% CI, 2.8 to 8.5). In the subgroup analyses according to type of RET fusions, ORR and median PFS were 83% (5/6) and 8.3 months in CCDC6-RET, 20% (2/10) and 2.9 months in KIF5B-RET and 67% (2/3) and 4.7 months in unknown. There were no significant differences for ORR and PFS among sex and smoking status. The most common adverse events were hypertension (84%), diarrhea (79%), rash (63%), dry skin (42%), and QT corrected interval prolonged (42%).


Vandetanib demonstrated effective antitumor activity and manageable safety profile in patients with advanced RET-rearranged NSCLC. The exploratory subgroup analyses demonstrated that tumors with CCDC6-RET fusion showed greater response to vandetanib than those with KIF5B-RET fusion.

Clinical trial identification


Legal entity responsible for the study



Grants from an Japan Agency for Medical Research and Development (AMED) Practical Research for Innovation Cancer Control.


K. Yoh, M. Satouchi, M. Nishio: Honoraria: AstraZeneca. Research funding: AstraZeneca. T. Seto: Honoraria: AstraZeneca, Sanofi. Research funding: AstraZeneca. N. Yamamoto, H. Murakami, N. Nogami: Honoraria: AstraZeneca. S. Nomura: Mr. Nomura received personal fees from Japan Breast Cancer Research Group (JBCRG), and grants from Japan Agency for Medical Research and Development (AMED), outside the submitted work. JBCRG: €500 - €20’000 AMED: €500 - €20’000. K. Goto: Research funding: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings